Abcam, ab192256, Anti-RUNX2 antibody [EPR14334]

Size: 20µL / 100µL / 1mL
Anti-RUNX2 antibody [EPR14334] (ab192256) is a rabbit monoclonal antibody detecting RUNX2 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IHC-P, ICC/IF . Suitable for Human, Mouse, Rat . - Biophysical QC for unrivalled batch-batch consistency - Over 110 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14334,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:ChIC/CUT&RUN-seq, Flow Cyt (Intra), ICC/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Below the target band, there are multi bands may be caused by protein degradation. We suggest customer to use freshly lysate to minimize protein degradation in western blot.

Product details:
Product Specifications
Anti-RUNX2 antibody [EPR14334] (ab192256) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ChIC/CUT&RUN-seq, Flow Cyt (Intra), ICC/IF, IHC-P and WB in human, mouse and rat samples.
Anti-RUNX2 antibody [EPR14334] (ab192256) specifically detects RUNX2 (UniProt ID: Q13950; Molecular weight: 57kDa) and is sold in 100 µL and 1 mL selling sizes.
Quality and Validation
Abcam's high quality manufacturing and validation processes ensure Anti-RUNX2 antibody [EPR14334] (ab192256) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-RUNX2 antibody [EPR14334] (ab192256) has been cited over 114 times in peer reviewed journals and is trusted by the scientific community.
Anti-RUNX2 antibody [EPR14334] (ab192256) has 8 independent reviews from customers.
Related Products
Antibody clone EPR14334 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 647 (
ab215954
ab215955
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RUNX2 also known as core-binding factor subunit alpha-1 (CBFA1) is a transcription factor with a molecular weight of approximately 56 kDa. It plays a pivotal role in regulating osteoblast differentiation and skeletal morphogenesis. This protein resides mainly in the nucleus and shows a high expression in bone tissue. RUNX2 binds to DNA sequences to control transcription of genes essential for bone development and maturation. The protein also possesses a Runt-homology domain enabling it to attach to specific DNA sequences.
Biological function summary
This protein orchestrates bone formation by influencing the expression of genes involved in osteoblast differentiation. RUNX2 operates as part of the larger transcriptional complex that includes other proteins that modulate its activity. It maintains bone homeostasis by regulating the expression of osteogenic markers including bone sialoprotein and osteocalcin. The ability of RUNX2 to drive osteoblast lineage commitment highlights its importance in skeletal health and development.
Pathways
RUNX2 shows significant involvement in both the Wnt signaling and TGF-beta signaling pathways. Within the Wnt signaling pathway RUNX2 interacts with beta-catenin to facilitate osteoblastogenesis and support bone matrix deposition. In the TGF-beta signaling pathway RUNX2 modulates Smad-dependent transcriptional activity important for extracellular matrix production and bone remodeling. These interactions illustrate RUNX2's central role in mediating bone development and maintenance.
RUNX2 mutations and dysregulation link to cleidocranial dysplasia a condition characterized by delayed closure of sutures in the skull and other skeletal anomalies. Additionally RUNX2 is related to osteosarcoma a type of bone cancer where its abnormal expression often contributes to tumor progression. In these contexts RUNX2 interacts with proteins like p53 an important regulator of cell cycle highlighting its influence on tumor suppressor networks and osteogenic pathways.